Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway

被引：1
|
作者：
Laird, A. D. [1 ]
Sillman, A. [2 ]
Sun, B. [2 ]
Mengistab, A. [2 ]
Chu, F. [3 ]
Lee, M. [3 ]
Cancilla, B. [3 ]
Aggarwal, S. K. [4 ]
Bentzien, F. [3 ]
机构：
[1] Exelixis, Translat Med, San Francisco, CA USA
[2] Exelixis, Mol & Cellular Pharmacol, San Francisco, CA USA
[3] Exelixis, Pharmacol, San Francisco, CA USA
[4] Exelixis, Clin Dev, San Francisco, CA USA
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72021-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：30 / 30
页数：1
相关论文
共 11 条
  • [1] Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor
    Shapiro, Geoffrey I.
    Edelman, Gerald
    Calvo, Emiliano
    Aggarwal, Sanjay K.
    Laird, A. Douglas
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3594S - 3594S
  • [2] Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
    Gravina, Giovanni Luca
    Mancini, Andrea
    Scarsella, Luca
    Colapietro, Alessandro
    Jitariuc, Ana
    Vitale, Flora
    Marampon, Francesco
    Ricevuto, Enrico
    Festuccia, Claudio
    TUMOR BIOLOGY, 2016, 37 (01) : 341 - 351
  • [3] Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
    Yu, Peiwen
    Laird, Douglas
    Du, Xiangnan
    Wu, Jianming
    Won, Kwang-Ai
    Yamaguchi, Kyoko
    Hsu, Pin Pin
    Qian, Fawn
    Jaeger, Christopher T.
    Zhang, Wentao
    Buhr, Chris A.
    Shen, Paula
    Abulafia, Wendy
    Chen, Jason
    Young, Jenny
    Plonowski, Arthur
    Yakes, F. Michael
    Chu, Felix
    Lee, Michelle
    Bentzien, Frauke
    Lam, Sanh Tan
    Dale, Stephanie
    Matthews, David J.
    Lamb, Peter
    Foster, Paul
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) : 1078 - 1091
  • [4] Biomarker development for XL765, a potent and selective oral dual inhibitor of PI3K and mTOR currently being administered to patients in a Phase I clinical trial
    Patnaik, Amita
    LoRusso, Patricia M.
    Tabernero, Josep
    Laird, A. Douglas
    Aggarwal, Sanjay K.
    Papadopoulos, Kyriakos P.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3516S - 3516S
  • [5] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Tabernero, Josep
    Markman, Ben
    Patnaik, Amita
    Tolcher, Anthony W.
    Baselga, Jose
    Shi, Weiliang
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Laird, A. Douglas
    Miles, Dale
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2014, 20 (09) : 2445 - 2456
  • [6] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Shapiro, Geoffrey I.
    Rodon, Jordi
    Bedell, Cynthia
    Kwak, Eunice L.
    Baselga, Jose
    Brana, Irene
    Pandya, Shuchi S.
    Scheffold, Christian
    Laird, A. Douglas
    Nguyen, Linh T.
    Xu, Yi
    Egile, Coumaran
    Edelman, Gerald
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 233 - 245
  • [7] Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation
    Thijssen, Rachel
    van Bochove, Gregor
    de Rooij, Martin F. M.
    ter Burg, Johanna
    Spaargaren, Marcel
    Egile, Coumaran
    Kersten, Marie Jose
    Eldering, Eric
    Kater, Arnon P.
    BLOOD, 2014, 124 (21)
  • [8] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)
    Rodon, Jordi
    Shapiro, G., I
    Bedell, C.
    Kwak, E. L.
    Baselga, J.
    Brana, I
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2192 - 2192
  • [9] The characterization and clinical significance of PI3K/Akt signaling pathway activation in the peripheral T cells of pediatric patients with atopic dermatitis
    Xiao, De-Qi
    Xu, Pei-Hong
    Deng, Hui
    Chen, Li-Sha
    Ding, Xu-An
    Bai, Mei
    Li, Pei
    Yuan, Ding-Fen
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (02): : 2904 - 2910
  • [10] Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of bcl-2 and Bcl-xL expression in endothelial cells
    Jin, YP
    Fishbein, MC
    Said, JW
    Jindra, PT
    Rajalingam, R
    Rozengurt, E
    Reed, EF
    HUMAN IMMUNOLOGY, 2004, 65 (04) : 291 - 302
12